Skip to main content

SpringWorks Therapeutics, Inc.

SWTXDelisted Jul 1, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001773427

SpringWorks Therapeutics, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.65B in total; Soros Fund Management was the only superinvestor holding it.

Q1 2022 vs. Q4 2021

How the institutions holding SpringWorks Therapeutics, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of SWTX: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders144136−8
Shares45.5M49.5M+4.00M (+8.8%)
Value$2.82B$2.79B−$25.8M (−0.9%)

New holders (14)

Institutions that held SpringWorks Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to SWTX in Q1 2022
InstitutionSharesValue% of portfolio
EcoR1 Capital, LLC325,881$18.4M0.58%
Natixis95,000$5.36M0.02%
Barclays PLC26,932$1.52M0.00%
Caption Management, LLC25,180$1.42M0.09%
Tudor Investment Corp Et Al15,755$889.0K0.02%
Jefferies Group LLC11,700$660.3K0.02%
Prudential Financial Inc9,930$560.0K0.00%
Blueshift Asset Management, LLC8,299$468.0K0.04%
Amalgamated Financial Corp.4,761$269.0K0.00%
E Fund Management Co., Ltd.4,557$257.0K0.01%
Cutler Group LP1,000$56.0K0.01%
Assetmark, Inc432$24.0K0.00%
Massmutual Trust Co FSB15$1.00K0.00%
Moisand Fitzgerald Tamayo, LLC23$1.00K0.00%

Sold out (22)

Institutions that held SpringWorks Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.